Joseph Rossano, MD, discusses how FDA approval of mavacamten introduces a disease-targeted treatment option for adolescents with symptomatic oHCM.
|Videos|March 21, 2022
What to look forward to at NAPNAP 2022
Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN, shares why she's excited for NAPNAP 2022 and what her "can't miss" sessions are.
Advertisement
Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN, a clinical professor at the Baylor University Louise Herrington School of Nursing sits down with Contemporary Pediatrics to discuss why she's excited for NAPNAP 2022 and what her "can't miss" sessions for the conference are.
Advertisement
Related to this article
Mavacamten becomes the first cardiac myosin inhibitor approved for adolescents aged 12 to younger than 18 years with symptomatic oHCM.
In a 48-patient phase 1b trial, ecnoglutide was well tolerated in adolescents with obesity and reduced BMI up to 12.6% at 20 weeks.
Can you guess the diagnosis?
DBV filed a BLA for the Viaskin peanut patch in peanut-allergic children aged 4-7, citing phase 3 VITESSE data, and requested priority review.
ScolimiR-3D, a 6-microRNA blood test to predict severe curve progression in AIS, received FDA Breakthrough Device designation.
Brian Vickery, MD, discusses a phase 1 trial evaluating the safety and tolerability of a microneedle stamp designed to deliver peanut protein through the skin.
The FDA approved tiratricol (Emcitate) for peripheral thyrotoxicosis in MCT8 deficiency, the first approved therapy for the rare disorder.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
BLA submitted to FDA for Viaskin peanut patch in children aged 4 to 7 years with peanut allergy
2
First-in-human trial tests microneedle stamp approach for peanut allergy
3
What the Camzyos approval means for adolescents with obstructive HCM
4
FDA approves tiratricol as first treatment for peripheral thyrotoxicosis in MCT8 deficiency
5